Can-Fite BioPharma Ltd - CANF Enterprise Value-to-Sales Ratio

Can-Fite BioPharma (CANF) relies on an asset-light model, delegating molecule synthesis to external contractors. The development strategy is based on licensing agreements with distributors worldwide and the monetization of patents through out-licensing. An enterprise valuation using EV/Sales helps identify the true trend within the sideways corridor, with the current value equal to -5804.88.
Can-Fite BioPharma, Ltd. - analytical breakdowns and key metrics (CANF)

This indicator determines the business value relative to its revenue, excluding the impact of debt load to provide an objective assessment of fundamental value. By analyzing the current EV/Sales level, an investor can see to what extent the market price of Can-Fite BioPharma (CANF) is justified by revenues, while the expected results of final clinical trials for liver disease drugs could serve as a key trigger for a revision of this multiple.